Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Inclusion Criteria: * Previously untreated, histologically confirmed follicular lymphoma, World Health Organization (WHO) classification grade I, II, or IIIa (\> 15 centroblasts per high power field with centrocytes present) that is stage III, IV, or bulky (i.e., single mass \>= 7 cm in any unidimensional measurement) stage II and requires therapy at the discretion of the primary physician * Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies; fine needle aspirates are not acceptable for diagnosis * Failure to submit pathology specimens within 60 days of patient registration will be considered a major protocol violation * Institutional flow cytometry or immunohistochemistry must confirm cluster of differentiation 20 (CD20) antigen expression * All risk by follicular lymphoma international prognostic index (FLIPI): 0-5 risk factors * No prior systemic therapy for non-Hodgkin lymphoma (NHL) including chemotherapy or immunotherapy (e.g., monoclonal antibody-based therapy), radiation therapy, or radioimmunotherapy * For non-NHL conditions, no chemotherapy, radiotherapy, or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of enrollment; no patients who have ongoing adverse events from agents administered more than 4 weeks previously * No prior exposure to any of the study agents * No corticosteroids within two weeks prior to study entry, except for maintenance therapy f…